Dexamethasone Intravitreal Implant at the Time of Cataract Surgery in Eyes with Diabetic Macular Edema

Abstract

Purpose

To determine the potential role of intraoperative dexamethasone intravitreal implant (DEX-I) in reducing diabetic macular edema (DME) worsening after phacoemulsification.

Methods

This was a prospective study on 19 eyes of 19 patients with type 2 diabetes mellitus with DME and cataract. Mean preoperative Early Treatment Diabetic Retinopathy Study visual acuity (VA) was 16.7 letters. Mean foveal thickness (FT) was 451 μm. The DME was naive in 11 eyes and refractory in 8 eyes. All eyes underwent a standard phacoemulsification and intraocular lens implantation; DEX-I was injected at the end of surgery. Follow-up was performed at 1 week and then monthly until DME recurrence (up to 8 months).

Results

At 1 week, mean VA improved by 15 letters (range 0-29 letters) and mean FT decreased by 147 μm (range 69-236 μm). Improvement consolidated at month 1, with a mean VA improvement of 18 letters (range 3-32 letters) and a mean improvement in FT of 193 μm (range 76-304 μm), remaining stable at month 2 after surgery in all eyes. The DME recurred in 1 eye at month 3, in 14 eyes (73.8%) between months 4 and 5, and after month 6 in 4 eyes (21%). Refractory DMEs demonstrated the same benefit but recurred earlier than naive ones (4 months versus 5.8 months, p<0.01).

Conclusions

Intraoperative DEX-I prevents DME worsening after phacoemulsification. Its positive effects last for at least 3 months.

Keywords

Cataract Dexamethasone intravitreal implant Diabetic macular edema Phacoemulsification

Get full access to this article

View all access options for this article.

References

Klein

Moss

Incidence of cataract surgery in the Wisconsin Epidemiologic Study of Diabetic Retinopathy.

Am J Ophthalmol 1995119(3)295–300

Klein

Wang

Moss

Older-onset diabetes and lens opacities.

The Beaver Dam Eye Study. Ophthalmic Epidemiol 19952(1)49–55

Foster

Wong

Machin

Johnson

Seah

Risk factors for nuclear, cortical and posterior subcapsular cataracts in the Chinese population of Singapore: the Tanjong Pagar Survey.

Br J Ophthalmol 200387(9)1112–1120

Nirmalan

Robin

Katz

et al.

Risk factors for age related cataract in a rural population of southern India: the Aravind Comprehensive Eye Study.

Br J Ophthalmol 200488(8)989–994

Raman

Pal

Adams

Rani

Vaitheeswaran

Sharma

Prevalence and risk factors for cataract in diabetes: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study, report no. 17.

Invest Ophthalmol Vis Sci 201051(12)6253–6261

Olafsdottir

Andersson

Stefánsson

The prevalence of cataract in a population with and without type 2 diabetes mellitus.

Acta Ophthalmol 201290(4)334–340 Published online December 16, 2011.

Sayin

Kara

Pekel

Ocular complications of diabetes mellitus.

World J Diabetes 20156(1)92–108

Hamilton

AMP

Ulbig

Polkinghorne.

Management of diabetic retinopathy London 1996

BMJ Publishing Group

19-23.

NCD Risk Factor Collaboration (NCD-RisC).

Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants. Lancet 2016387100027 1513–30

10.

Baker

Almukhtar

Bressler

et al;

Diabetic Retinopathy Clinical Research Network Authors/Writing Committee.

Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema. JAMA Ophthalmol 2013131(7)870–879

11.

Dowler

JGF

Sehmi

Hykin

Hamilton

The natural history of macular edema after cataract surgery in diabetes.

Ophthalmology 1999106(4)663–668

12.

Giocanti-Aurégan

Grenet

Fajnkuchen

Chaine

(Impact of cataract surgery on central macular thickness in diabetic patients without diabetic retinopathy).

J Fr Ophtalmol 201336(1)35–40

13.

Sadiq

Sleep

Amoaku

The visual results and changes in retinopathy in diabetic patients following cataract surgery.

Eur J Ophthalmol 19999(1)14–20

14.

Chung

Kim

Yoo

Lee

Effect of cataract surgery on the progression of diabetic retinopathy.

J Cataract Refract Surg 200228(4)626–630

15.

Pollack

Dotan

Oliver

Progression of diabetic retinopathy after cataract extraction.

Br J Ophthalmol 199175(9)547–551

16.

Henricsson

Heijl

Janzon

Diabetic retinopathy before and after cataract surgery.

Br J Ophthalmol 199680(9)789–793

17.

Chylack

Jr Wolfe

Singer

et al;

The Longitudinal Study of Cataract Study Group.

The lens opacities classification system III. Arch Ophthalmol 1993111(6)831–836

18.

Panozzo

Gusson

Panozzo

Dalla

Mura G

Dexamethasone intravitreal implant for diabetic macular edema: indications for a PRN regimen of treatment.

Eur J Ophthalmol 201525(4)347–351

19.

Jaffe

Burton

Progression of nonproliferative diabetic retinopathy following cataract extraction.

Arch Ophthalmol 1988106(6)745–749

20.

Baker

Almukhtar

Bressler

et al;

Diabetic Retinopathy Clinical Research Network Authors/Writing Committee.

Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema. JAMA Ophthalmol 2013131(7)870–879

21.

Chu

Johnston

Buscombe

Sallam

Mohamed

Yang

United Kingdom Pseudophakic Macular Edema Study Group.

Risk Factors and Incidence of Macular Edema after Cataract Surgery: A Database Study of 81984 Eyes. Ophthalmology 2016123(2)316–323 Published online December 8, 2015.

22.

Chae

Joe

Yang

et al.

Effect of combined cataract surgery and ranibizumab injection in postoperative macular edema in nonproliferative diabetic retinopathy.

Retina 201434(1)149–156

23.

Rauen

Ribeiro

Almeida

Scott

Messias

Jorge

Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema.

Retina 201232(9)1799–1803

24.

Salehi

Beni

Razmjoo

Beni

Phacoemulcification with intravitreal bevacizumab injection in patients with cataract and coexisting diabetic retinopathy: prospective randomized study.

J Ocul Pharmacol Ther 201228(3)212–218

25.

Wahab

Ahmed

Management of cataract with macular oedema due to diabetes mellitus type-II and hypertension with grid laser prior to surgery and intra-vitreal bevacizumab (Avastin) peroperatively.

J Pak Med Assoc 201060(10)836–839

26.

Akinci

Muftuoglu

Altınsoy

Ozkılıc

Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract.

Retina 201131(4)755–758

27.

Kuppermann

Blumenkranz

Haller

et al;

Dexamethasone DDS Phase II Study Group.

Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007125(3)309–317

28.

Furino

Boscia

Recchimurzo

Sborgia

Alessio

Intravitreal dexamethasone implant for macular edema following uncomplicated phacoemulsification.

Eur J Ophthalmol 201424(3)387–391

29.

Khurana

Palmer

Porco

Wieland

Dexamethasone intravitreal implant for pseudophakic cystoid macular edema in patients with diabetes.

Ophthalmic Surg Lasers Imaging Retina 201546(1)56–61

30.

Agarwal

Gupta

Ram

Gupta

Dexamethasone intravitreal implant during phacoemulsification.

Ophthalmology 2013120(1)211 211.e1-211.e5.

31.

Boyer

Yoon

Belfort

Jr et al;

Ozurdex MEAD Study Group.

Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014121(10)1904–1914

32.

Haller

Bandello

Belfort

Jr et al;

OZURDEX GENEVA Study Group.

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010117(6)1134–1146.e3

33.

Augustin

Kuppermann

Lanzetta

et al;

Ozurdex MEAD Study Group.

Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol 2015 15 150

34.

Gusson

Panozzo

Casati

Dexamethasone intravitreal implant at the time of cataract surgery in patients with macular edema.

Invest Ophthalmol Vis Sci 201354(15)2384